Inivata Boosts Executive Team with appointment of Clive Morris as Chief Medical Officer

2016, News

Inivata, a global clinical cancer genomics company employing the precision of circulating tumour DNA (ctDNA) analysis to improve personalised healthcare in oncology, today announces the appointment of Professor Clive Morris as Chief Medical Officer. Clive will provide medical leadership across the clinical development programme, scientific collaborations, and through to commercialisation ensuring that Inivata’s products help deliver significant improvements in clinical outcomes for patients.

Clive joins Inivata from Health Innovation Manchester, an initiative to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services. Previous to this, Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and most recently led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ. Clive is a proven leader in the biopharmaceutical industry and has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. He’s accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, as well as holding an Executive MBA and Honorary Professorship of Translational Medicine at the University of Manchester. Clive is also a non-executive director of Wheatsheaf investments and the recently launched InnovateUK Medicines Discovery Catapult.

Michael Stocum, Chief Executive Officer at Inivata, said: 

“We are delighted to welcome Clive to the Inivata executive team in this period of rapid growth following our recent funding round. His oncology and medical expertise is fundamental to our success as we undertake a series of clinical studies to validate our broad molecular profiling ctDNA platform and move ahead with commercialisation. I look forward to working with Clive in both our US and UK labs.”



Clive Morris, Chief Medical Officer at Inivata, said: 

“Analysis of ctDNA has huge potential to help oncologists manage their patients more effectively and I look forward to helping Inivata play a major part in this transformation. I’m really pleased to be joining the team at such an exciting time for the company and the ctDNA field generally.”

Inivata recently completed a £31.5 million in Series A round, securing funds to accelerate clinical studies and validation of its technology platform for the analysis of ctDNA, (eTAm-SeqTM) and commercialise its first products. Analytical validation, presented in April at AACR, showed its broad molecular profiling as a robust and reproducible method of detecting genomic alterations in ctDNA with high sensitivity and specificity. Inivata’s proprietary platform will be applied across a spectrum of solid tumours to provide oncologists with clinically actionable information to stratify patients, monitor treatment progress, and identify emerging tumour resistance.


About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to Follow us on Twitter @Inivata.


Media Contacts

Consilium Strategic Communications

Chris Gardner/Angela Gray/Sarah Wilson

Paul Rabin (US) +44 (0)20 3709 5700, +1 516 503 0271


Karen Chandler-Smith +44 (0)7900 430235


Our Technology

Our Solutions

Latest News

LinkedIn tracking code Twitter tracking code